Vioxx for migraine
Executive Summary
Merck's COX-2 inhibitor Vioxx (rofecoxib) clears FDA for the acute treatment of migraines in adults March 26. Pfizer has submitted an sNDA for Bextra in the treatment of migraines; the application has an estimated user fee date in September...
You may also be interested in...
Merck Vioxx Approved For Migraine, Giving Edge Over Pfizer COX-2 Inhibitors
Merck's COX-2 inhibitor Vioxx is adding a migraine pain indication for the 25 mg and 50 mg doses
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.